Physician profile
Nan E Means
NPI 1134368848
$6,922.31
in general payments reported to CMS, 2019-2025
29 companies · $2,627 in 2025
The $2,627 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $692 · 2022: $850 · 2023: $1,463 · 2024: $1,291 · 2025: $2,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,151 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,150.98 |
| Education | $229.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,379.75 | 2021-2025 | |
| Amgen INC. | $930.73 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $478.24 | 2022-2025 | |
| Janssen Biotech, INC. | $411.83 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $393.14 | 2022-2025 | Ilumya |
| Ucb, INC. | $307.03 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $276.20 | 2022-2025 | Taltz, Zepbound, Ebglyss |
| Teva Pharmaceuticals USA, INC. | $229.15 | 2025 | Austedo Xr |
| Janssen Scientific Affairs, LLC | $228.55 | 2022-2023 | Xarelto, Stelara |
| Axsome Therapeutics, INC. | $213.06 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $205.47 | 2021-2024 | Lokelma |
| Dexcom, INC. | $205.35 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $204.19 | 2022-2024 | Sotyktu |
| Pfizer INC. | $160.27 | 2021-2025 | |
| Genzyme Corporation | $138.21 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $123.82 | 2025 | Fanapt |
| Horizon Therapeutics Plc | $123.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $121.50 | 2022 | |
| Eisai INC. | $121.40 | 2024 | |
| Sanofi-Aventis U.S. LLC | $120.58 | 2025 | |
| Insmed, INC. | $111.90 | 2025 | Arikayce |
| Biohaven Pharmaceutical Holding Company LTD. | $107.58 | 2022 | |
| Novo Nordisk INC | $104.50 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $103.61 | 2025 | |
| Genentech USA, INC. | $42.43 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $30.48 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $19.56 | 2022 | |
| Leo Pharma INC. | $17.65 | 2022 | |
| Organon LLC | $12.71 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Means listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.